Citius Pharmaceuticals, Inc. (CTXR) Fair Value 2026

CTXR · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

3.7 /10

32 fundamental signals · 1 models active

Value Trap Risk

DANGER (61/100)

Quick Summary — As of 2026-08-28, Citius Pharmaceuticals, Inc. (CTXR) trades at $0.60. QOC: 3.7/10. Value Trap Risk: 61/100 (DANGER). 1/13 models active.

Key Facts

Ticker
CTXR
Price
$0.60
Quality Score
3.7/10
Value Trap Risk
61/100
Models Active
1/13
Last Updated
Strength: PWERM suggests +135.0% upside with 35% confidence
Risk: Value Trap score of 61 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give CTXR?

1 Intrinsic Value Models vs. Current Price ($0.60)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $1.42 +135.0%

All Models Active

All 1 models are displayed above.

What Is Citius Pharmaceuticals, Inc. (CTXR) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for Citius Pharmaceuticals, Inc.. Trading at $0.60 against an estimated intrinsic value of $1.42, 1 of 1 active models flag meaningful upside of +135.0% at the median.

What Do the Models Say About CTXR?

1 of 13 models are currently active for CTXR. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does CTXR Rank in Biotechnology?

Among 625 Biotechnology stocks, CTXR ranks #559 by Quality of Company score. CirclFi's QOC score of 3.7/10 evaluates 32 fundamental signals. A score of 3.7 signals below-average fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a biotech sector, Citius Pharmaceuticals, Inc. operates in a sector where partnership revenue is a critical driver of valuation. Investors evaluating CTXR should weigh these sector-specific dynamics alongside our model-derived fair values.

Is CTXR a Value Trap?

CirclFi's Value Trap algorithm assigns CTXR a score of 61/100 (DANGER). This is a high-risk signal. Deteriorating fundamentals suggest the discount may be justified. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Citius Pharmaceuticals, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Citius Pharmaceuticals, Inc.'s fundamental quality profile registers 3.7/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record. Investors should note the company's elevated value trap risk score, which suggests apparent undervaluation may not be what it seems.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CTXR valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across CTXR's 1 active models, average confidence is 35%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Citius Pharmaceuticals, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

AEONAEON Biopharma, Inc.QOC 3.7SKYESkye Bioscience, Inc.QOC 3.7ABPOAbpro Holdings, Inc.QOC 3.8BIVIBioVie Inc.QOC 3.7OCEAOcean Biomedical, Inc.QOC 3.8PBLSParabilis Medicines, Inc.QOC 3.7AGIOAgios Pharmaceuticals, Inc.QOC 6.5APLMApollomics, Inc.QOC 5.3FTHFaeth Therapeutics, Inc.QOC 4.7EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: AEON · SKYE · ABPO · BIVI · OCEA · PBLS · AGIO · APLM · FTH · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to CTXR?

7 companies across all industries closest to CTXR’s Quality of Company score of 3.7/10.

QNTQuantinuum Inc.QOC 3.7TGLOtheglobe.com, inc.QOC 3.7OFRMOnce Upon A Farm, PBCQOC 3.7LUDGLudwig Enterprises, Inc.QOC 3.7CHGAChange Agents CorporationQOC 3.7BTZBlackRock Credit Allocation Income TrustQOC 3.7NVDANVIDIA CorporationQOC 10.0

Read investment analysis: QNT · TGLO · OFRM · LUDG · CHGA · BTZ · NVDA

Where Does CTXR Sit in CirclFi's Biotechnology Rankings?

CTXR is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Citius Pharmaceuticals, Inc.’s Valuation?

What is Citius Pharmaceuticals, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Citius Pharmaceuticals, Inc. (CTXR). The Quality of Company score is 3.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CTXR overvalued or undervalued right now?

At $0.60, 1 of 1 active models suggest CTXR may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Citius Pharmaceuticals, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 3.7 mean for CTXR?

Citius Pharmaceuticals, Inc.'s QOC of 3.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on CTXR?

CirclFi analyzes CTXR with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is CTXR a value trap in 2026?

Citius Pharmaceuticals, Inc.'s Value Trap score is 61/100 (DANGER). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Citius Pharmaceuticals, Inc. (CTXR) a Quality of Company score of 3.7/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/CTXR/ · Methodology
Primary sources for this CTXR valuation
  • Financial statements: Citius Pharmaceuticals, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001506251) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for CTXR as of ; valuations recomputed .